Research location

Newport Beach

California, United States

View saved research

Published trials599

Site observations619

Linked trials published599

Page1 / 12

Research activity in Newport Beach

California, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 599 trials and 619 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Newport Beach

599 linked trials · page 1 of 12

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)NCT07711691 · 2026-09-16 · 1 site observation

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT07793409 · 2026-09-16 · 1 site observation

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245 · 2026-08-07 · 1 site observation

Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361 · 2026-08-01 · 1 site observation

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionNCT07661329 · 2026-06-02 · 2 site observations

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04 · 1 site observation

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDNCT07610395 · 2026-05-01 · 1 site observation

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475 · 2026-04-30 · 1 site observation

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesNCT07304154 · 2026-04-10 · 1 site observation

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialNCT07288034 · 2026-04-08 · 1 site observation

A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)NCT07355270 · 2026-04-01 · 1 site observation

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical PracticeNCT07556159 · 2026-04-01 · 1 site observation

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the LungNCT07499674 · 2026-03-31 · 1 site observation

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry StudyNCT07676565 · 2026-03-24 · 1 site observation

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaNCT07456033 · 2026-03-13 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694 · 2026-02-11 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation

A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791 · 2025-10-22 · 1 site observation

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173 · 2025-10-22 · 1 site observation

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339 · 2025-10-20 · 1 site observation

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01 · 1 site observation

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNCT06765109 · 2025-07-17 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · 2025-06-27 · 1 site observation

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsNCT06993844 · 2025-06-10 · 1 site observation

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 1 site observation

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · 2025-05-20 · 1 site observation

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)NCT06783309 · 2025-05-12 · 1 site observation

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerNCT06827236 · 2025-04-23 · 1 site observation

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28 · 1 site observation

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · 2025-03-26 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate CancerNCT06609005 · 2025-01-23 · 1 site observation

A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963 · 2025-01-07 · 1 site observation

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaNCT06651567 · 2024-10-22 · 1 site observation

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)NCT06633016 · 2024-09-20 · 1 site observation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseaseNCT06540833 · 2024-08-15 · 1 site observation

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)NCT06362252 · 2024-07-22 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.